A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

Claudia Worth; Hussein Al-Mossawi; Joanne MacDonald; Benjamin Fisher; Antoni Chan; Raj Sengupta; Jon Packham; Karl Gaffney; Nicola Gullick; Jonathan Cook; Tim Corn; James Teh; Pedro Machado; Peter Taylor; Paul Bowness

A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

Claudia Worth^*, Hussein Al-Mossawi, Joanne MacDonald, Benjamin Fisher, Antoni Chan, Raj Sengupta, Jon Packham, Karl Gaffney, Nicola Gullick, Jonathan Cook, Tim Corn, James Teh, Pedro Machado, Peter Taylor, Paul Bowness

^*Corresponding author for this work

Inflammation and Ageing

Research output: Contribution to journal › Article › peer-review

Abstract

Original language	English
Journal	The Lancet Rheumatology
Publication status	Accepted/In press - 15 Apr 2024

Bibliographical note

Not yet published as of 16/04/2024.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Embargoed Document

WorthC2024first
Accepted author manuscript, 439 KB
Licence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Embargo ends: 14/05/24

Cite this

Worth, C., Al-Mossawi, H., MacDonald, J., Fisher, B., Chan, A., Sengupta, R., Packham, J., Gaffney, K., Gullick, N., Cook, J., Corn, T., Teh, J., Machado, P., Taylor, P., & Bowness, P. (Accepted/In press). A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study). The Lancet Rheumatology.

@article{6f91b05b69e145b4851ea67cfb1edee5,

title = "A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)",

author = "Claudia Worth and Hussein Al-Mossawi and Joanne MacDonald and Benjamin Fisher and Antoni Chan and Raj Sengupta and Jon Packham and Karl Gaffney and Nicola Gullick and Jonathan Cook and Tim Corn and James Teh and Pedro Machado and Peter Taylor and Paul Bowness",

note = "Not yet published as of 16/04/2024.",

year = "2024",

month = apr,

day = "15",

language = "English",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

}

Worth, C, Al-Mossawi, H, MacDonald, J, Fisher, B, Chan, A, Sengupta, R, Packham, J, Gaffney, K, Gullick, N, Cook, J, Corn, T, Teh, J, Machado, P, Taylor, P & Bowness, P 2024, 'A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)', The Lancet Rheumatology.

TY - JOUR

T1 - A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

AU - Worth, Claudia

AU - Al-Mossawi, Hussein

AU - MacDonald, Joanne

AU - Fisher, Benjamin

AU - Chan, Antoni

AU - Sengupta, Raj

AU - Packham, Jon

AU - Gaffney, Karl

AU - Gullick, Nicola

AU - Cook, Jonathan

AU - Corn, Tim

AU - Teh, James

AU - Machado, Pedro

AU - Taylor, Peter

AU - Bowness, Paul

N1 - Not yet published as of 16/04/2024.

PY - 2024/4/15

Y1 - 2024/4/15

UR - https://www.thelancet.com/journals/lanrhe/home

M3 - Article

SN - 2665-9913

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

ER -

A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

Abstract

Bibliographical note

UN SDGs

Embargoed Document

Fingerprint

Cite this